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OBJECTIVE: This study evaluated attitude of physicians
toward formularies as well as services provided by the
pharmacy department in a large independent practice as-
sociation (IPA). METHODS: Surveys (n  280) were
sent to all practitioners in the IPA. The survey requested
information on physician use of and satisfaction with the
existing printed formulary quick list, their satisfaction
with the pharmacy services, and their attitude towards
formularies in general using a five-point strongly agree-
strongly disagree scale. We received 90 completed sur-
veys with a response rate of 32%. RESULTS: Majority of
respondents were staff physicians (87%). Around 31%
indicated pediatrics as their specialization followed by
family medicine (17%) and internal medicine (17%).
Practitioners who indicated that they had received the
formulary quick list (37%) were highly satisfied (3.44 
0.84) with it. Practitioners were very satisfied with the
performance (4.27  0.79), interaction (4.35  0.81),
and services offered (4.21  0.79) by the pharmacies.
Their attitude towards pharmacist playing a more active
role in patient care was positive (3.54  0.98). However,
their attitude towards formularies in general was nega-
tive. They agreed that formularies increased the amount
of time spent making drug choices (4.01  1.1), limited
access to the best medicines for patients (3.63  0.88),
resulted in less-effective medicines (3.01  0.99), com-
promised the quality of drugs prescribed (3.36  0.92),
and reduced the opportunities to offer the best medica-
tion for patients (3.43  0.82). CONCLUSION: Physi-
cians had negative attitude towards formularies in gen-
eral. However, they were satisfied with the services
offered by pharmacists, and they were positive towards
more patient care involvement by the pharmacists. Physi-
cians were also satisfied with the formulary quick list of-
fered by the pharmacy department. A plan was developed
to provide practitioners with an interactive, intranet-
based reference of medications that would assist in pre-
scribing decisions.
PHP3
PHARMACOECONOMIC FELLOWSHIPS: 
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The escalating demand for pharmacoeconomic research
has exceeded the supply of available researchers. Post-
graduate pharmacoeconomic fellowships emerged to
train and produce quality independent researchers to
meet these growing educational needs. However, even af-
ter more than ten years in existence, the effectiveness of
these programs has not been formally evaluated. In order
to determine their effectiveness, first, a set of measures
for pharmacoeconomic fellowship programs needs to be
developed. OBJECTIVE: To construct a framework to
examine the potential structure, process, and outcome
measures for pharmacoeconomic fellowship programs.
METHODS: Using the Donabedian model, we discuss
the structures, processes, and outcomes of pharmacoeco-
nomic fellowship programs. RESULTS: We begin by fo-
cusing on the structure of these programs, including facil-
ities, qualification of the teaching staff, and operations of
the institution. The types of settings involved in pharma-
coeconomic fellowships are illustrated, and the experi-
ence and skills of preceptors and fellowship applicants
are defined. The processes of pharmacoeconomic fellow-
ships are reviewed, and the different characteristics of
these programs such as the research and the educational
components are discussed. Potential outcome measures
of pharmacoeconomic fellowship programs are dis-
cussed. CONCLUSION: A framework for examining the
structure, process, and outcome measures for pharmaco-
economic fellowship programs is given. Measures evalu-
ating the outcomes of fellowship programs need to be de-
veloped. Further research is needed to determine the
effectiveness of pharmacoeconomic fellowship programs.
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Pharmaceutical benefit management (PBM) programs are
key to the provision of prescription drugs among those
enrolled in health plans. A recent survey of HMOs re-
vealed 600 of 604 HMOs had a drug benefit; and only 57
HMOs of the 600 with a drug benefit did not provide
prescription drug coverage through a PBM (PBMI, 2000).
Several proposals have advocated use of PBMs to admin-
ister outpatient prescription drug benefits for Medicare
enrollees. Thus, the demand for accountability and a
means to evaluate performance of PBM programs is
growing; yet a set of standardized indicators for evaluat-
ing PBM performance does not yet exist. OBJECTIVE:
Explore the array of functions performed by PBMs and
measures used to evaluate PBM performance. Recom-
mend additional measures that should be considered to-
ward development of a comprehensive measurement set
for evaluating PBM activities. METHODS: MEDLINE
and web searches were conducted to develop a summary
of PBM functions and existing PBM-related indicators.
Measures used in other performance measurement activi-
ties that could be modified to assess PBM performance
also were identified. RESULTS: PBM activities fall into
four major categories: (1) administrative and manage-
ment, (2) drug use control, (3) cost containment, and (4)
disease management. Monitoring costs and savings of us-
ing drug management programs is the main focus of PBM
performance measurement to date. Several entities have
participated in efforts to develop measures for evaluating
pharmaceutical care, but none has defined a comprehen-
sive set of performance measures. Additional measures
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that could be included in a comprehensive measurement
set, falling into the four major categories of PBM activities,
are suggested. CONCLUSIONS: A standardized, compre-
hensive set of performance indicators should be developed
to enable public and private sector purchasing organiza-
tions to evaluate PBM services and the impact of these
activities on quality of care and consumer satisfaction.
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OBJECTIVES: Poland is the next European country,
which is in the process of drafting country-specific guide-
lines for economic evaluation of pharmaceuticals. The
aim of the study was to compare Polish pharmacoeco-
nomic guidelines with international health economic
guidelines, highlighting areas of agreement and dissent.
METHODS: Existing documents from 18 countries were
reviewed, analyzed and a comparison was undertaken.
The following topics were considered: objective, use of
pharmacoeconomic analyses, responsibility in their con-
duct and target audience, methodology and ethical code
of practice while conducting and publishing results of
pharmacoeconomic analysis. The explanation of differ-
ences was taken. RESULTS: For a number of issues rec-
ommendations are consistent between Poland and other
countries. For the purpose of the Polish pharmacoeco-
nomic research guidelines, the Canadian, Australian,
Dutch and Belgian guidelines have, in some parts, been
specially adopted to the Polish situation. In some parts it
was possible to combine certain aspects; in the other, due
to the unique local circumstances, there was a need to de-
velop the methodological guidelines on a pure national
level. For example there is a lack of consensus concerning
costing and utility measurement. CONCLUSIONS: The
guidelines for conducting pharmacoeconomic evaluations
are linked to existing health care system and approaches
to the pricing and reimbursement of pharmaceuticals.
This is the purpose of differences between international
health economic guidelines. To reach an optimal degree
of the use of pharmacoeconomic studies in decision-mak-
ing process it is essential to take into account local situa-
tion and create country-specific guidelines.
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OBJECTIVES: The pharmacoeconomic litrature shows
that one of the means available to HMOs for wisely us-
ing the medical budget is the Pharmacy and Therapeutics
Committee (PTC). The present procedure for the hospital
PTCs was written by the Ministry of Health in 1978. The
aim of the study was to investigate the Israeli hospitals
PTCs work. METHODS: This study was based upon a
questionnarire which included subjects from the PTCs
procedure and also subjects that the PTC dealt with in
the late nineties. The questionnarire was sent in October
1999 to 51 hospitals. The information was processed on
Excel software. RESULTS: Hospital responses were 41/
51 (80.4%). Thirty one hospitals reported having PTC
and answered the questionnaire, ten hospitals reported
not-having PTC at all. The PTCs chairperson appointed
is a department director as demanded by the Ministry
Procedure by 12 (41%) of the hospitals, the deputy chair-
person nomination matched by 2 (7%) hospitals, orga-
nizer of the PTC nomination matched by 20 (69%) of the
hospitals. The attending doctors specialities are: intern,
pediatrics, surgery, gynecology, infection diseases, anes-
thesiology and mental health. Nine (31%) hospitals re-
ported having a PTC procedure, 28 (97%) hospitals are
checking requests for enlarging the local formulary and
just 25 (86%) recommend of formulary reduction; 20
(69%) hospital PTCs recommended 50 guidelines to the
local management and 28 of them were addopted. CON-
CLUSION: From the returned questionaries it seems that
no PTC keeps the entire procedure. In 1999, the local
PTCs reported adding 494 medicines and decreasing 48,
which means a total of 446 medicines added. One hun-
dred seventy nine members of PTCs formed 50 guide-
lines; 28 of them were accepted by the local management.
There is no control of the Ministry of Health on the PTCs
procedures implementation; the procedure has not been
upgraded since 1978 and it is not familiar to most of the
hospitals.
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OBJECTIVES: The field of health economics (HE) has
undergone vast growth over the last decade. One contin-
ually evolving main factor is the motivation for perform-
ing HE studies, in particular in Canada because of chang-
ing requirements for provincial formulary submissions.
The objective of this study was to determine how HE
data is being applied by the Canadian pharmaceutical in-
dustry to date. METHODS: A survey was sent to key
personnel working in HE in the Canadian pharmaceuti-
cal industry and followed-up. Data from returned surveys
were compiled in a database, tabulated, and evaluated.
RESULTS: Twenty-one (84%) of 25 surveys sent to com-
panies reporting previous experience with HE were re-
